Medtronic received CE Mark approval and is launching the Resolute Onyx drug eluting stent (DES). It’s modeled on the Resolute Integrity DES, but features a dense metal core surrounded by a cobalt alloy outer layer. This permits it to have more strength while having narrower struts, and being better seen under a fluoroscope.
The combination of these advancements should help physicians to deliver the stent with more confidence and be able to place it within challenging lesions.
The device is yet to receive FDA clearance and is currently not available in the U.S.
More details from Medtronic:
CoreWire Technology is the next new DES advancement after Continuous Sinusoid Technology (CST), which was previously introduced with the Resolute Integrity DES and the Integrity bare-metal stent. CST is a method of stent manufacturing that molds one single strand of wire into a sinusoidal wave enabling a continuous range of motion.
“CoreWire Technology is an exciting innovation that will have measurable impact on clinical practice today and tomorrow,” said Jason Weidman, vice president and general manager of the coronary and renal denervation business unit at Medtronic. “The advancements of the Resolute Onyx DES specifically address the need for continued procedural efficiency and ease-of-use. Importantly, and in contrast to some current DES technologies, it achieves meaningful deliverability enhancement with no compromise to stent strength.”
Available in a broad size matrix (including a new 2.0 mm diameter), the CE mark labeling for Resolute Onyx DES includes information on one month of dual antiplatelet therapy (DAPT).